{{Rsnum
|rsid=2303137
|Chromosome=5
|position=35895623
|Orientation=minus
|GMAF=0.4812
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 19.5 | 36.3 | 44.2
| HCB | 49.6 | 43.1 | 7.3
| JPT | 57.5 | 34.5 | 8.0
| YRI | 2.0 | 24.5 | 73.5
| ASW | 3.5 | 49.1 | 47.4
| CHB | 49.6 | 43.1 | 7.3
| CHD | 48.6 | 43.1 | 8.3
| GIH | 40.6 | 39.6 | 19.8
| LWK | 8.2 | 40.9 | 50.9
| MEX | 37.9 | 41.4 | 20.7
| MKK | 10.9 | 43.6 | 45.5
| TSI | 22.5 | 46.1 | 31.4
| HapMapRevision=28
}}

{{omim
|desc=MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 3; MS3
|id=612595
|rsnum=2303137
}}

{{PharmGKB
|RSID=rs2303137
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17660816
|Annotation=In a case-control study of Nordic populations, rs2303137 was associated with risk of multiple sclerosis.
|Drugs=
|Drug Classes=
|Diseases=Multiple Sclerosis
|Curation Level=Curated
|PharmGKB Accession ID=PA162356128
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2303137
|overall_frequency_n=53
|overall_frequency_d=128
|overall_frequency=0.414062
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=38
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}